We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Abcam, Integer Holdings and RxSight
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abcam plc , Integer Holdings Corp. (ITGR - Free Report) and RxSight Inc. (RXST - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
3 Medical Device Stocks with Potential to Fight Deflation Risk
Amid rate hikes by the Fed to tame inflation, a risk of deflation looms. The Fed has increased interest rates by 5% in almost one and a half years to mitigate the risk of rising prices. However, there are concerns that the significant rise in interest rate in such a short period of time may lead to deflation.
Risk of Deflation
Per Morgan Stanley analyst Mike Wilson's podcast, the U.S. economy may face deflation or falling prices, which could hurt corporate earnings and stock prices.
Wilson said that inflation, which has eased recently, is likely to come down faster than expected due to the lagged effect of rate hike by the Federal Reserve. This could lead to not just disinflation, but outright deflation, where prices decline. He warned that deflation would reduce companies' pricing power and future earnings, which would be detrimental to stocks. Wilson added that stock valuations are already quite extended and deflation can prove harmful for earnings growth.
He pointed at several signs of deflation, such as falling housing prices, car prices, and even prices of airlines and hotels, and advised that equity investors should be careful for what they wish for, as falling inflation was great news for the Fed, but not for stocks.
Contrarian View
In this YouTube video, Wall Street analyst Jim Bianco warns that the U.S. economy could face further setbacks as the Fed continues to raise interest rates to fight inflation. He says that core inflation, which excludes food and energy, is still too high at 5% over the last six months. Bianco thinks that the Fed has not yet reached the neutral or restrictive level of monetary policy. He also thinks that inflation is more persistent than the markets expect and that the economy will not slow down enough to lower it. Bianco notes that the Fed has already hiked rates by 5% since April 2022 and that higher rates have caused some financial stress in the past.
Stock Market Impact of Potential Deflation
Per this Business Insider article, Wermuth Asset Management states that stocks are "dangerously overpriced" as the S&P 500 has surged 16% this year, despite the weakening outlook for corporate earnings. It is of the view that businesses could face lower profits as financial conditions remain tight and inflation cools off. Per a Morgan Stanley's prediction, this could lead to one of the worst earnings recessions since 2008 and a 16% drop in stocks.
Wermuth Asset Management also highlights the trouble in the commercial real estate market, where $1.5 trillion debt will soon need to be refinanced, but interest rates are higher and banks are less willing to lend. The Capital Economics estimates that this could cause commercial property prices to crash 40%.
A falling inflation will be driven by a slowing GDP growth across major global economies, including the United States.
Now, we discuss three medical device stocks — Abcam plc, Integer Holdings Corp. and RxSight Inc. — with market cap in the range of $1-$5 billion, Zacks Rank #1 (Strong Buy) or #2 (Buy) and strong long-term growth outlook. A robust outlook suggests potential uptrend for these stocks going forward that will help offset deflationary and recessionary risks.
3 Medical Device Stocks to Bet on Potential Deflation Risk
Abcam is a life sciences company. It researches, develops and distributes biological reagents and tools for research, drug discovery and diagnostics. The company operates principally in the United States, China, Japan, Germany, the United Kingdom and internationally.
The favorable Zacks Rank also makes it a suitable bet for investors. The Zacks Consensus Estimate for 2023 earnings and revenues is pegged at 44 cents per share and $531.8 million, respectively, indicating a year-over-year growth rate of 46.7% and 32.6%.
Integer Holdings manufactures and develops medical devices and components primarily for original equipment manufacturers that depend on it to design, develop and produce intellectual property protected medical device technologies.
The company carries a Zacks Rank of 2 at present. Its earnings are estimated to grow at a rate of 12.1% for the next five years. ABCM's earnings beat estimates in each of the last four quarters, delivering an average surprise of 8.43%. The Zacks Consensus Estimate for 2023 earnings and revenues is pinned at $4.53 per share and $1.54 billion, respectively, implying a year-over-year growth rate of 11.6% and 11.8%.
RxSight is a commercial-stage medical technology company focused on patients following cataract surgery. The RxSight Light Adjustable Lens system comprises of the RxSight Light Adjustable Lens(R), RxSight Light Delivery Device and accessories.
The company currently carries a Zacks Rank of 2. Its earnings are estimated to grow at a rate of 19% for the next five years. RXST's earnings beat estimates in each of the last four quarters, delivering an average surprise of 17.3%. The Zacks Consensus Estimate for 2023 earnings is pinned at a loss of $1.66 per share and the same for revenues is pegged at $84.14 million, reflecting year-over-year improvement of 31.1% and 71.7%, respectively.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Abcam, Integer Holdings and RxSight
For Immediate Release
Chicago, IL – August 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abcam plc , Integer Holdings Corp. (ITGR - Free Report) and RxSight Inc. (RXST - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
3 Medical Device Stocks with Potential to Fight Deflation Risk
Amid rate hikes by the Fed to tame inflation, a risk of deflation looms. The Fed has increased interest rates by 5% in almost one and a half years to mitigate the risk of rising prices. However, there are concerns that the significant rise in interest rate in such a short period of time may lead to deflation.
Risk of Deflation
Per Morgan Stanley analyst Mike Wilson's podcast, the U.S. economy may face deflation or falling prices, which could hurt corporate earnings and stock prices.
Wilson said that inflation, which has eased recently, is likely to come down faster than expected due to the lagged effect of rate hike by the Federal Reserve. This could lead to not just disinflation, but outright deflation, where prices decline. He warned that deflation would reduce companies' pricing power and future earnings, which would be detrimental to stocks. Wilson added that stock valuations are already quite extended and deflation can prove harmful for earnings growth.
He pointed at several signs of deflation, such as falling housing prices, car prices, and even prices of airlines and hotels, and advised that equity investors should be careful for what they wish for, as falling inflation was great news for the Fed, but not for stocks.
Contrarian View
In this YouTube video, Wall Street analyst Jim Bianco warns that the U.S. economy could face further setbacks as the Fed continues to raise interest rates to fight inflation. He says that core inflation, which excludes food and energy, is still too high at 5% over the last six months. Bianco thinks that the Fed has not yet reached the neutral or restrictive level of monetary policy. He also thinks that inflation is more persistent than the markets expect and that the economy will not slow down enough to lower it. Bianco notes that the Fed has already hiked rates by 5% since April 2022 and that higher rates have caused some financial stress in the past.
Stock Market Impact of Potential Deflation
Per this Business Insider article, Wermuth Asset Management states that stocks are "dangerously overpriced" as the S&P 500 has surged 16% this year, despite the weakening outlook for corporate earnings. It is of the view that businesses could face lower profits as financial conditions remain tight and inflation cools off. Per a Morgan Stanley's prediction, this could lead to one of the worst earnings recessions since 2008 and a 16% drop in stocks.
Wermuth Asset Management also highlights the trouble in the commercial real estate market, where $1.5 trillion debt will soon need to be refinanced, but interest rates are higher and banks are less willing to lend. The Capital Economics estimates that this could cause commercial property prices to crash 40%.
A falling inflation will be driven by a slowing GDP growth across major global economies, including the United States.
Now, we discuss three medical device stocks — Abcam plc, Integer Holdings Corp. and RxSight Inc. — with market cap in the range of $1-$5 billion, Zacks Rank #1 (Strong Buy) or #2 (Buy) and strong long-term growth outlook. A robust outlook suggests potential uptrend for these stocks going forward that will help offset deflationary and recessionary risks.
3 Medical Device Stocks to Bet on Potential Deflation Risk
Abcam is a life sciences company. It researches, develops and distributes biological reagents and tools for research, drug discovery and diagnostics. The company operates principally in the United States, China, Japan, Germany, the United Kingdom and internationally.
This Zacks Rank #2 company's earnings are expected to witness a CAGR of 28.8%, reflecting strong growth potential for the stock. You can see the complete list of today's Zacks #1 Rank stocks here.
The favorable Zacks Rank also makes it a suitable bet for investors. The Zacks Consensus Estimate for 2023 earnings and revenues is pegged at 44 cents per share and $531.8 million, respectively, indicating a year-over-year growth rate of 46.7% and 32.6%.
Integer Holdings manufactures and develops medical devices and components primarily for original equipment manufacturers that depend on it to design, develop and produce intellectual property protected medical device technologies.
The company carries a Zacks Rank of 2 at present. Its earnings are estimated to grow at a rate of 12.1% for the next five years. ABCM's earnings beat estimates in each of the last four quarters, delivering an average surprise of 8.43%. The Zacks Consensus Estimate for 2023 earnings and revenues is pinned at $4.53 per share and $1.54 billion, respectively, implying a year-over-year growth rate of 11.6% and 11.8%.
RxSight is a commercial-stage medical technology company focused on patients following cataract surgery. The RxSight Light Adjustable Lens system comprises of the RxSight Light Adjustable Lens(R), RxSight Light Delivery Device and accessories.
The company currently carries a Zacks Rank of 2. Its earnings are estimated to grow at a rate of 19% for the next five years. RXST's earnings beat estimates in each of the last four quarters, delivering an average surprise of 17.3%. The Zacks Consensus Estimate for 2023 earnings is pinned at a loss of $1.66 per share and the same for revenues is pegged at $84.14 million, reflecting year-over-year improvement of 31.1% and 71.7%, respectively.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.